Trial · NCT07477418
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
NCT07477418, Phase 1, Phase 2, Not yet recruiting, University of Vermont
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP). Trials, record NCT07477418. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07477418
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
- NCT number
- NCT07477418
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- University of Vermont
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
- Interventions
- Gemcitabine Delivered by Transarterial Microperfusion
- First posted
- 2026-03-17
- Last updated
- 2026-03-17
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of Neoadjuvant Transarterial Gemcitabine Delivery | 3 years | Safety and tolerability will be assessed by the incidence, severity, and relationship of adverse events associated with transarterial microperfusion delivery of gemcitabine. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. |
| Secondary | Surgical Margin Status | At the time of surgical resection | Surgical margin status will be assessed on the resected surgical specimen following completion of neoadjuvant therapy. Margin status will be categorized based on pathologic evaluation as margin-negative (R0) or margin-positive (R1 or R2) according to standard institutional pathology criteria. |
| Secondary | Pathologic Tumor Regression | At the time of surgical resection | Pathologic tumor regression will be assessed on the surgical resection specimen following completion of neoadjuvant therapy. Tumor response will be evaluated by a pathologist using a standardized tumor regression grading system to characterize the extent of residual viable tumor relative to treatment-related changes. |
| Secondary | Pancreatic Duct Size | At the time of surgical resection | Intraoperative pancreatic duct size. |
| Secondary | Maintenance of Chemotherapy Relative Dose Intensity | From start of chemotherapy to surgery resection | The proportion of participants who maintain a relative dose intensity of at least 80% during neoadjuvant modified FOLFIRINOX chemotherapy will be assessed based on delivered doses relative to planned doses over the chemotherapy treatment period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07477418
GET https://conductscience.org/api/trials/v1/NCT07477418/registered